Telavancin for injection (Vibativ): Lipoglycopeptide antibiotic approved for the treatment of complicated skin and skin-structure infectionsOctober 1st 2009
New molecular entity: Telavancin for injection (Vibativ) was approved on September 11, 2009, for the treatment of complicated skin and skin-structure infections (cSSSIs)
Global health concerns generate new therapies for home and abroadSeptember 1st 2009
Even before the emergence of the swine flu pandemic, biopharmaceutical companies were investing in vaccines and treatments for lethal diseases that plague much of the world. There is growing recognition that Americans and Europeans are vulnerable to infections from overseas, and that development of new medications is critical to ensuring public health.
Bevacizumab (Avastin): Monoclonal antibody approved for the treatment of metastatic renal cell carcinoma in combination with interferon alfaSeptember 1st 2009
New indication: Bevacizumab (Avastin), a monoclonal antibody, was approved on July 31, 2009, for the treatment of metastatic renal cell carcinoma in combination with interferon alfa
P&T considerations in fashioning a knowledge base, action plan for cardiometabolic disorders and weightSeptember 1st 2009
The P&T committee is positioned to provide knowledge, strategies to improve treatment of patients with cardiometabolic disorders.
Sumatriptan (Sumavel DosePro): Needle-free injection of 5-HT1 receptor agonist approved for the acute treatment of migraine and cluster headachesSeptember 1st 2009
New formulation: Sumatriptan (Sumavel DosePro) formulated as a needle-free injection was approved on July 15, 2009, for the acute treatment of migraine and cluster headaches
Golimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseasesSeptember 1st 2009
Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
IVIg treatment associated with a reduced risk of Alzheimer's diseaseAugust 1st 2009
In a retrospective analysis published in the journal Neurology, investigators demonstrated that previous treatment with intravenous immunoglobulin (IVIg) was associated with a reduced risk of the development of Alzheimer's disease and related disorders (ADRD) in patients aged at least 65 years.
Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III
This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.
Rivaroxaban: A direct factor Xa inhibitor for VTE prophylaxis in patients undergoing total knee or hip replacement surgeryAugust 1st 2009
Rivaroxaban is a highly potent direct factor Xa inhibitor that is pending FDA approval for the indication of venous thromboembolism (VTE) prophylaxis in patients undergoing total knee replacement or total hip replacement surgery.
Dronedarone (Multaq): Benzofuran derivative approved to reduce the risk of CV hospitalization in patients with AFAugust 1st 2009
New molecular entity: Dronedarone (Multaq), a benzofuran derivative, was approved on July 1, 2009, to reduce the risk of CV hospitalization in patients with AF
Prasugrel (Effient): Platelet activation and aggregation inhibitor approved to reduce the rate of thrombotic CV events in patients with ACS undergoing PCIAugust 1st 2009
New molecular entity: Prasugrel (Effient), a platelet activation and aggregation inhibitor, was approved on July 10, 2009, to reduce the rate of thrombotic CV events in patients with ACS undergoing PCI
Tadalafil (Adcirca): Phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (WHO Group I)July 1st 2009
New indication: Tadalafil (Adcirca), a phosphodiesterase type 5 inhibitor, was approved on May 22, 2009, for the treatment of pulmonary arterial hypertension (WHO Group I)
Tolvaptan (Samsca): Vasopressin receptor antagonist approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremiaJuly 1st 2009
New molecular entity: Tolvaptan (Samsca), a vasopressin receptor antagonist, was approved on May 19, 2009, for the treatment of clinically significant hypervolemic and euvolemic hyponatremia
Milnacipran: A serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia syndromeJuly 1st 2009
Milnacipran was recently approved by FDA for the management of fibromyalgia syndrome. Clinical trials have demonstrated that this agent may be a reasonable alternative or adjunct therapy for patients with fibromyalgia syndrome who are unable to tolerate first-line tricyclic antidepressant therapy.
Golimumab associated with risk of serious fungal infectionsJune 15th 2009
Centocor Ortho Biotech has issued a Dear Healthcare Professionals letter to remind healthcare providers that golimumab (Simponi), a tumor necrosis factor (TNF)-alpha blocker, is associated with a risk of serious fungal infections.
Serious ADRs associated with psychotropic use in childrenMay 15th 2009
Prescribing psychotropic medications for attention-deficit/hyperactivity disorder (ADHD) and other disorders in children is common around the world, even though serious adverse drug reactions (ADRs) have been reported with the use of these drugs, said speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida.
Rivaroxaban superior to enoxaparin in preventing VTE after knee arthroplastyMay 15th 2009
Results from the Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism 4 (RECORD4) trial published in Lancet demonstrated that rivaroxaban 10 mg once daily is superior to subcutaneous (SC) enoxaparin in preventing venous thromboembolism (VTE) after total knee arthroplasty.
Comparative effectiveness research may shape treatment, coverage decisionsMay 1st 2009
The economic stimulus package approved by Congress in February provides more than $1 billion to support research on competing medical treatments. Although a fairly minor piece of the larger $789 billion American Recovery and Reinvestment Act of 2009 (ARRA), the provision set off widespread reaction to the possibility that comparative study results may be used to limit coverage of more expensive medicines.
Osteoarthritis: A review of treatment optionsMay 1st 2009
Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in the United States, especially among older adults. This article reviews nonpharmacologic and pharmacologic approaches to management of OA of the knee and hip.